PRDX-4: a novel biomarker similar to KL-6 for predicting the occurrence and progression of systemic sclerosis-ILD.

IF 1.9 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2025-05-01 Epub Date: 2025-04-01 DOI:10.1080/17520363.2025.2485014

Gizem Tuğçe Alp, İbrahim Vasi, Emre Alp, Aslıhan Avanoğlu Güler, Hazan Karadeniz, Özlem Gülbahar, Abdulsamet Erden, Abdurrahman Tufan, Mehmet Akif Öztürk, Berna Göker, Şeminur Haznedaroğlu, Hamit Küçük

{"title":"PRDX-4: a novel biomarker similar to KL-6 for predicting the occurrence and progression of systemic sclerosis-ILD.","authors":"Gizem Tuğçe Alp, İbrahim Vasi, Emre Alp, Aslıhan Avanoğlu Güler, Hazan Karadeniz, Özlem Gülbahar, Abdulsamet Erden, Abdurrahman Tufan, Mehmet Akif Öztürk, Berna Göker, Şeminur Haznedaroğlu, Hamit Küçük","doi":"10.1080/17520363.2025.2485014","DOIUrl":null,"url":null,"abstract":"Aim: Lungs are among the most affected organs in systemic sclerosis (SSc), with interstitial lung disease (ILD) being a leading cause of mortality. Biomarkers are increasingly explored for predicting SSc-ILD detection and progression. This study evaluates the roles of Krebs von den Lungen-6 (KL-6), surfactant protein D (SP-D), and peroxiredoxin-4 (PRDX-4) in diagnosing SSc-ILD and monitoring progression.Methods: A total of 89 individuals (61 SSc patients and 28 healthy volunteers) were included. SSc patients were grouped based on pulmonary function tests and high-resolution computed tomography findings to determine SSc-ILD presence. Patients with SSc-ILD were further categorized by progressive pulmonary fibrosis (PPF) presence based on 2022 guidelines. Serum KL-6, SP-D, and PRDX-4 levels were measured using the Enzyme-Linked Immuno-Sorbent Assay method.Results: Of the 61 SSc patients, 34 (55.7%) had ILD. Serum KL-6 and PRDX-4 levels were significantly higher in SSc-ILD patients (p = 0.004 and p = 0.012, respectively). KL-6, SP-D, and PRDX-4 levels were elevated in the PPF group compared to stable disease (p = 0.001). PRDX-4 showed the highest diagnostic performance for PPF (AUC: 0.936, sensitivity: 85.7%, specificity: 85%).Conclusion: KL-6 is a well-established biomarker for SSc-ILD, but PRDX-4 offers superior diagnostic accuracy, especially in identifying PPF.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"349-355"},"PeriodicalIF":1.9000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051532/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2485014","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Lungs are among the most affected organs in systemic sclerosis (SSc), with interstitial lung disease (ILD) being a leading cause of mortality. Biomarkers are increasingly explored for predicting SSc-ILD detection and progression. This study evaluates the roles of Krebs von den Lungen-6 (KL-6), surfactant protein D (SP-D), and peroxiredoxin-4 (PRDX-4) in diagnosing SSc-ILD and monitoring progression.

Methods: A total of 89 individuals (61 SSc patients and 28 healthy volunteers) were included. SSc patients were grouped based on pulmonary function tests and high-resolution computed tomography findings to determine SSc-ILD presence. Patients with SSc-ILD were further categorized by progressive pulmonary fibrosis (PPF) presence based on 2022 guidelines. Serum KL-6, SP-D, and PRDX-4 levels were measured using the Enzyme-Linked Immuno-Sorbent Assay method.

Results: Of the 61 SSc patients, 34 (55.7%) had ILD. Serum KL-6 and PRDX-4 levels were significantly higher in SSc-ILD patients (p = 0.004 and p = 0.012, respectively). KL-6, SP-D, and PRDX-4 levels were elevated in the PPF group compared to stable disease (p = 0.001). PRDX-4 showed the highest diagnostic performance for PPF (AUC: 0.936, sensitivity: 85.7%, specificity: 85%).

Conclusion: KL-6 is a well-established biomarker for SSc-ILD, but PRDX-4 offers superior diagnostic accuracy, especially in identifying PPF.

查看原文本刊更多论文

PRDX-4：一种类似于KL-6的新型生物标志物，可预测系统性硬化症- ild的发生和进展。

目的：肺是系统性硬化症（SSc）中最受影响的器官之一，而间质性肺疾病（ILD）是导致死亡的主要原因。越来越多的生物标志物被用于预测SSc-ILD的检测和进展。本研究评估了Krebs von den Lungen-6 （KL-6）、表面活性剂蛋白D （SP-D）和过氧化物还原素-4 （PRDX-4）在SSc-ILD诊断和监测进展中的作用。方法：共纳入89例个体（SSc患者61例，健康志愿者28例）。根据肺功能检查和高分辨率计算机断层扫描结果对SSc患者进行分组，以确定SSc- ild的存在。根据2022年指南，SSc-ILD患者进一步根据进行性肺纤维化（PPF）进行分类。采用酶联免疫吸附法测定血清KL-6、SP-D和PRDX-4水平。结果：61例SSc患者中，34例（55.7%）有ILD。SSc-ILD患者血清KL-6和PRDX-4水平显著升高（p = 0.004和p = 0.012）。与病情稳定的患者相比，PPF组的KL-6、SP-D和PRDX-4水平升高（p = 0.001）。PRDX-4对PPF的诊断价值最高（AUC: 0.936，敏感性：85.7%，特异性：85%）。结论：KL-6是一种成熟的SSc-ILD生物标志物，但PRDX-4具有更高的诊断准确性，特别是在识别PPF方面。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.